Perils of Pain Meds

TASA ID: 13340

This article originally appeared in The Rheumatologist, 2008 - https://www.the-rheumatologist.org/article/perils-of-pain-meds/ and has been granted permission to be republished on The TASA Group website.

Over the last decade, an expansion in the use of opioids has been advocated by certain pain specialists as well as pharmaceutical companies. In my opinion, this has occurred in the absence of valid data that support the claims that opioids can effectively and safely be extended beyond cancer to most patients with chronic non-cancer pain with a low risk of addiction. Such claims have subsequently been found to be inaccurate, and the original statement about the low rate of addiction to a common oxycodone sustained-release formulation has been shown to be false (as recently admitted by pharmaceutical company executives as a result of a Federal indictment).

TASA Article Disclaimer

This article discusses issues of general interest and does not give any specific legal or business advice pertaining to any specific circumstances.  Before acting upon any of its information, you should obtain appropriate advice from a lawyer or other qualified professional.

This article may not be duplicated, altered, distributed, saved, incorporated into another document or website, or otherwise modified without the permission of TASA and the author (TASA ID#: 13340). Contact marketing@tasanet.com for any questions.